Merited Wealth’s Amneal Pharmaceuticals AMRX Stock Holding History

Merited Wealth’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-510	Closed	-$6.43K	–	92
2025 Q4	$6.43K	Buy	+510	New	+$5.83K	0.01%	213

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Merited Wealth's AMRX Position: Q1 2026 in Review

Merited Wealth sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 510 shares — an estimated $6.43K sold.

Merited Wealth first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $6.43K in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Merited Wealth reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Merited Wealth sold 510 Amneal Pharmaceuticals shares in Q1 2026, an estimated $6.43K.
Merited Wealth first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Merited Wealth's Amneal Pharmaceuticals position peaked at $6.43K in Q4 2025.
316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Merited Wealth's 13F filing for Q1 2026, filed 24 Apr 2026.